Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cytokine. 2003 Feb 21;21(4):179-86.

Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice.

Author information

  • 1Department of Medicine I, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany. dr_bojunga@web.de

Abstract

AIMS/HYPOTHESIS:

T-cell activation by specific antigen has been found to increase macrophage migration inhibitory factor (MIF) expression, indicating its role as an important feature of T-cell activation in vitro and in vivo. To date, the potential role of MIF in the development of autoimmune-mediated diabetes mellitus has not been studied.

METHODS:

MIF-mRNA expression in splenic lymphocytes of spontaneously diabetic non-obese diabetic (NOD) mice (n=6), cyclophosphamide-treated NOD mice (n=6), 14-day-old non-diabetic NOD mice (n=7) and C57/Bl6 control mice (n=6) was monitored using an internally standardised competitive reverse transcription-polymerase chain reaction, and the MIF-protein levels were determined using Western blot analysis. In addition, the impact of intraperitoneally administered recombinant MIF-protein treatment on diabetes incidence in NOD mice was evaluated.

RESULTS:

MIF-mRNA expression was markedly increased in splenic lymphocytes of spontaneously diabetic NOD mice as well as in 8-week-old NOD mice treated with cyclophosphamide compared with 2-week-old non-diabetic NOD and healthy C57BL/6 control mice. Western blot analyses showed decreased lymphocytic MIF-protein content in diabetic as well as in cyclophosphamide-treated animals compared with 2-week-old non-diabetic NOD and healthy C57BL/6 mice, probably as a consequence of increased protein secretion. Furthermore, treatment of NOD mice with recombinant MIF-protein at 25 microg twice a week, from age 6 to 11 weeks, led to an increased diabetes incidence (86%; n=7) compared with untreated control groups (55%; n=20) at week 34.

CONCLUSIONS/INTERPRETATION:

In this study, we report for the first time that MIF-mRNA expression in splenic lymphocytes is up-regulated during development of cell-mediated diabetes in non-NOD mice. The data of our preliminary study suggest a possible role of MIF in autoimmune-inflammatory events, such as type-1 diabetes and also that anti-MIF therapeutic strategy might serve to attenuate autoimmune processes.

PMID:
12788306
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk